
==== Front
Curr Genomics
Curr Genomics
CG
Current Genomics
1389-2029
1875-5488
Bentham Science Publishers

38751599
CG-25-120
10.2174/0113892029280454240214072212
Life Sciences, Genetics & Genomics, Genetics & Heredity
Effect of Calebin-A on Critical Genes Related to NAFLD: A Protein-Protein Interaction Network and Molecular Docking Study
Mahmoudi Ali 12
Hajihasani Mohammad Mahdi 3
Majeed Muhammed 4
Jamialahmadi Tannaz 5
Sahebkar Amirhossein 67*
1 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
2 Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
3 Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;
4 Department of Chemistry, Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ, 08520, USA;
5 Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;
6 Department of Medical Biotechnology, Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;
7 Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
* Address correspondence to this author at the Department of Medical Biotechnology, Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; E-mail: amir_saheb2000@yahoo.com
22 2 2024
2024
25 2 120139
11 10 2023
12 1 2024
01 2 2024
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Background

Calebin-A is a minor phytoconstituent of turmeric known for its activity against inflammation, oxidative stress, cancerous, and metabolic disorders like Non-alcoholic fatty liver disease(NAFLD). Based on bioinformatic tools. Subsequently, the details of the interaction of critical proteins with Calebin-A were investigated using the molecular docking technique.

Methods

We first probed the intersection of genes/ proteins between NAFLD and Calebin-A through online databases. Besides, we performed an enrichment analysis using the ClueGO plugin to investigate signaling pathways and gene ontology. Next, we evaluate the possible interaction of Calebin-A with significant hub proteins involved in NAFLD through a molecular docking study.

Results

We identified 87 intersection genes Calebin-A targets associated with NAFLD. PPI network analysis introduced 10 hub genes (TP53, TNF, STAT3, HSP90AA1, PTGS2, HDAC6, ABCB1, CCT2, NR1I2, and GUSB). In KEGG enrichment, most were associated with Sphingolipid, vascular endothelial growth factor A (VEGFA), C-type lectin receptor, and mitogen-activated protein kinase (MAPK) signaling pathways. The biological processes described in 87 intersection genes are mostly concerned with regulating the apoptotic process, cytokine production, and intracellular signal transduction. Molecular docking results also directed that Calebin-A had a high affinity to bind hub proteins linked to NAFLD.

Conclusion

Here, we showed that Calebin-A, through its effect on several critical genes/ proteins and pathways, might repress the progression of NAFLD.

Keywords

Calebin-A
functional enrichment analysis
GEO
molecular docking
NAFLD
prediction databases
PPI network
==== Body
pmc1 INTRODUCTION

A prominent cause of chronic liver disease globally is non-alcoholic fatty liver disease (NAFLD), which influences a considerable proportion of the community in many parts of the world [1]. Hepatic steatosis, the major symptom of NAFLD, occurs when no other reasons for secondary liver fat deposition (such as excessive alcohol use) can be found. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD that might progress into fibrosis and cirrhosis [2, 3]. Steatosis is evident in NAFLD without any signs of inflammation. Still, when coupled with lobular inflammation and apoptosis, it can lead to non-alcoholic steatohepatitis (NASH) and subsequent ramifications such as fibrosis and cirrhosis [4, 5]. The incidence of NAFLD has grown quickly in Western nations, with a global prevalence of 25%. NAFLD is linked to metabolic diseases such as central obesity, hypertension, dyslipidemia, chronic abnormalities, and hyperglycemia [6]. The gold standard for diagnosing NAFLD is histological assessment using a liver biopsy. NAFLD is diagnosed based on hepatic steatosis, and its severity varies according to the presence of lobular inflammation, ballooning, and fibrosis [6]. The growing prevalence of NAFLD worldwide, coupled with its risk of progressing to more advanced liver disease states, represents a major public health challenge. Furthermore, the lack of any pharmacological agent approved for NAFLD highlights the urgent need for novel treatment options to address this disorder.

Calebin-A was originally isolated from Curcuma longa [7] and then discovered in Curcuma caesia [8]. Various evidence has revealed the value of these plants in modern medicine as prophylactic agents against inflammation [9], oxidative stress [10], and cancer [11-13]. This secondary phytochemical indicates safe properties even at a high dose [14]. Calebin-A is an aglycone, glucuronidated metabolite that has a serum half-life of approximately 1-3 hours and largely non-renal excretion [10].

Calebin-A was found to repress adipogenesis through suppression of adipocyte differentiation at an early stage and decreasing several key modulators such as peroxisome proliferator-activated receptor γ (PPARγ), fatty acid synthase (FAS), and CCAAT/enhancer-binding protein (C/EBP) α/β in adipocytes. Calebin-A was discovered to cause lipolysis at 20 µM and simultaneously facilitate AMP-activated protein kinase (AMPK) activity. Moreover, Calebin-A could protect against metabolic syndrome and decrease hepatic steatosis in mice fed a high-fat diet (HFD) [15], along with weight reduction and blood glucose control (15). In a separate study, Calebin-A was found to exert anti-obesity effects by regulating thermogenesis and gut microbiota and enhancing intestine commensal bacteria like Butyricoccus and Akkermansia [16]. Permanent inflammatory processes are the root of the majority of illnesses. Calebin-A can impact several pro-inflammatory signaling pathways [17].

In the last decade, numerous bioinformatic tools have appeared to help scientists speed up target identification and drug discovery. This field is comprised of a combination of computer science and molecular biology. These technologies offer a wide variety of information, including genomics, transcriptomics, and proteomics, as well as epigenomics, pharmacogenomics, metagenomics, and metabolomics [18]. The most common usage of those in silico studies included high-throughput transcriptomics analysis and protein-protein interaction (PPI) networks to find critical targets related to particular diseases [19, 20]. Also, virtual screening and molecular docking are time- and cost-effective compared to the conventional deconvolution and investigation approach to determining the relationship between drugs and diseases [21-25]. Molecular docking is a computer-based technique that simulates the interaction of small molecules to macromolecular targets' structures and evaluates whether they could complement the binding site [26, 27].

While some previous studies have investigated the biological effects and therapeutic potential of Calebin-A, its mechanisms of action in NAFLD and specific protein targets remain unclear from an in silico perspective. A few studies have used high-throughput techniques to characterize differentially expressed genes in NAFLD patients and animal models. However, an integrated computational analysis linking Calebin-A, NAFLD targets, and their molecular interactions has not been reported.

In this study, we aimed to 1) identify potential protein targets of Calebin-A associated with NAFLD pathogenesis using in silico databases and PPI network analysis and 2) explore the molecular interactions between Calebin-A and relevant protein targets through docking studies. We hypothesize that Calebin-A modulates NAFLD by binding to and regulating key protein targets involved in hepatic lipid metabolism and inflammation. Elucidating the mechanism of Calebin-A action may aid the development of new therapeutic strategies for NAFLD. A flowchart is shown in Fig. (1) to depict the study's design visually.

2 MATERIALS AND METHODS

2.1 Calebin-A and Target Search

We first searched several important prediction databases like www.swisstargetprediction, https://prediction.charite.de/, http://targetnet.scbdd.com/, http://gdbtools.unibe.ch:8080/PPB/browser.html, to find the possible targets of Calebin-A. These databases have specific algorithms that could predict possible targets for Calebin-A based on the 2D/3D Structure of Calebin-A that imported data in all the databases, usually in SMILES format of the small molecules [28-31].

2.2 Exploring NAFLD-gene Associations

2.2.1 Data Source

The expression profile GSE135251 based on GPL18573 Illumina NextSeq 500 platform was acquired from the Omnibus database (GEO). The GEO database freely and openly shares vast gene expression and other omics datasets internationally to further the molecular study of biological systems through distributed archives of high-throughput transcriptional profiles [32]. The data included 206 patients with different stages of NAFLD and 10 healthy people. We used this database to achieve an overexpressed gene set in the NAFLD.

2.2.2 Identification of Differentially Expressed Genes

The GSE raw count matrix was downloaded from the GEO database. The count matrix was exported to R (version 4.2.1), and the METADATA related to the GSE number was obtained by the GEOquery package. We used the “limma” and “edgeR” packages for normalization and differential expression analysis. For normalization, DGEList and calcNormFactors methods were applied. A specific size factor for each sample was deliberated, and each gene count was divided by this size factor. NAFLD and Control were set as the independent variables for significance testing. After normalization, the differential gene expression was calculated by an exact Test based on Benjamini and Hochberg (False discovery rate). Furthermore, |logFC| >0 with adjusted P-value < 0.05 was considered as the cut-off for the output data differentially expressed genes (DEGs). Moreover, the samples based on the DEGs heatmap and volcano plot were drawn with the ggplot2 package for visualizing and grouping.

2.2.3 Assay of the Intersection of Essential Proteins of NAFLD and Calebin A

The Venn diagram evaluated the intersection of all achieved targets from prediction databases with overexpressed genes achieved in GSE135251 (https://bioinfogp.cnb.csic.es/tools/venny/).

2.2.4 Protein-protein Interaction (PPI) Network and MCODE Analysis

Based on the above methodology, the Protein-Protein interaction (PPI) network was constructed from intersection targets of two achieved databases. In this case, first, we used the STRING website (https://string-db.org/) to find the interaction among the genes/proteins. STRING is a comprehensive and integrative source that contains physical and functional protein-protein interactions based on in silico knowledge or experimental validation [33]. A medium confidence score >0.4 was and species limitation to the “Homo sapiens” considered. Subsequently, analysis of the PPI network was accomplished based on important centralities like Degree (as topological algorithms) and Betweenness and Closeness (as shortest paths) [34]. Moreover, the clustering was performed using the Molecular Complex Detection (MCODE) algorithm [35]. All the analyses were done using Cytoscape version 3.9.1 software with NetworkAnalyzer (version 4.4.8) and MCODE (version 2.0.2) plugins.

2.5 Molecular Docking

2.5.1 Target Proteins and Ligand Preparation

The structure of Calebin-A in a single structure document (SDF) format was obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). PubChem is an open chemistry database known as an important chemical information resource that comprises small and large molecule structures, identifiers, biological activities, and chemical and physical properties [36]. We explored the potential direct interaction of essential hub proteins related to NAFLD with Calebin-A by Molecular docking. The energy of the molecules was minimized and then transformed to PDBQT (Protein Data Bank, Partial Charge (Q), and Atom Type (T)) format to use Vina for the docking process. AutoDock Vina is a freely available computational tool for exploring possible binding conformations between macromolecules and ligand molecules through in-silico docking simulations [37]. The 3D structure of proteins (in PDB format) was taken from the RCSB PDB web server (http://www.pdb.org/). The RCSB PDB is a protein 3D structural database achieved with various methods like nuclear magnetic resonance (NMR) and X-ray crystallography [38].

2.5.2 Molecular Docking Process

We first primed the structure of selected proteins by UCSF Chimera software (version 1.8.1), and then, the operation of docking was performed against Clebin-A in PyRx software with 500 exhaustiveness. We employed UCSF Chimera software to facilitate the preparation of ligands for molecular docking simulations. This involved utilizing the software's capabilities to add hydrogen atoms, assign partial charges, optimize structures, and address any structural issues or inconsistencies that may arise [39].

PyRx is software for docking a set of small molecules against macromolecules in one run [40]. The result of molecular docking is reported by binding energy (ΔGbind). Finally, the H-bind interactions were analyzed using Discovery Studio Visualizer 4.5.

2.5.3 KEGG and Gene Ontology Enrichment Analysis

KEGG and gene ontology (Biological process, molecular functions, and cellular component) were estimated with the ClueGO+CluePedia version 1.5.9 program. ClueGO is a Cytoscape plugin for investigating the interrelationships of gene sets to achieve their function [41]. KEGG contains a collection of databases associated with genomes, diseases, biological pathways, chemical substances, and drugs [42].

2.5.4 ADME Estimation

We evaluate the absorption, distribution, metabolism, and excretion (ADME) of Calebin-A to investigate their drug-likeness potential using http://www.swissadme.ch.

3 RESULTS

The investigation of the possible targets for Calebin-A in the prediction databases was reported in Table 1. The results found 317 unique targets for Calebin-A. Conversely, the analysis of GSE135251 included 4852 up-regulated and 4042 down-regulated. The clustering of genes among the samples was indicated in the Heatmap (Fig. 2A). Moreover, differential gene expression (Fold-change), along with significant (downregulate (green) and upregulate (orange)), is visualized in Fig. (2B).

Next, in Venn diagram analysis among two datasets (Calebin-A-related targets VS NAFLD-related genes), we observed 87 intersected genes (Fig. 3).

The PPI network that was created contained 83 nodes and 315 edges. The analysis of the main centralities showed that Tumor Protein p53 (TP53), Tumor Necrosis Factor (TNF), Signal transducer and activator of transcription 3 (STAT3), Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1), Prostaglandin-Endoperoxide Synthase 2 (PTGS2), Histone deacetylase 6 (HDAC6), ATP-binding cassette subfamily B member 1 (ABCB1), Chaperonin Containing TCP1 Subunit 2 (CCT2), nuclear receptor subfamily 1 (NR1I2), and glucuronidase beta (GUSB) are the Hub genes that have the most impact on the PPI network (Fig. 4, Table 2).

In addition, the MCODE analysis identified three modular clusters in the PPI network. The highest score cluster (MCODE 1) comprises 11 nodes and 40 edges with 8.00 scores and seed: ABCB1. MCODE2 was set up with 11 nodes, 22 edges, and a score of 4.40, seed: HDAC3. MCODE3 was identified with a score of 3.33, seed BRCA1, node of 4, and edge of 5 (Fig. 5).

The highest adjusted P-value pathways in the KEGG enrichment of 87 shared genes/ proteins (intersection of overexpressed genes related to NAFLD ∩ Calebin-A targets) were relevant with Sphingolipid signaling pathway with 9.24% associated genes percent and P-value: 9.33E-10, Vascular endothelial growth factor A (VEGFA) signaling pathway with 11.86% associated genes percent and P-value: 3.09E-07, C- type lectin receptor signaling pathway with 7.69% associated genes percent and P-value: 7.69%, and Mitogen-Activated Protein Kinase (MAPK) signaling pathway with 3.40% associated genes percent and P-value: 6.40E-06 (Fig. 6A).

Functional enrichment analysis at the biological process level proposed regulation of apoptotic process with 2.56% associated genes percent and P-value: 6.36E-07, positive regulation of cytokine production with 3.88% associated genes percent and P-value: 2.02E-06, positive regulation of intracellular signal transduction with 2.75% associated genes percent and P-value: 7.69E-06 (Fig. 6B). Besides, under molecular function, the analysis revealed that 87 intersection proteins/ genes were mainly applied in protein kinase binding with 2.96%associated genes percent and P-value: 1.20E-06, transcription regulatory region nucleic acid binding with 4.25% associated genes percent and P-value: 4.77E-05, kinase binding with 2.60% associated genes percent and P-value: 5.27E-05, and sphingosine-1-phosphate receptor activity with 60.00% associated genes percent and P-value: 5.27E-05 (Fig. 6C). Additionally, an intracellular membrane-bounded organelle with 1.22% associated genes percent and P-value: 1.18E-08, a nucleus with 0.94% associated genes percent and P-value: 4.88E-06, secretory granule lumen with 2.85% associated genes percent and P-value: 3.21E-04, and ficolin-1-rich granule with 3.80% associated genes percent and P-value: 3.25E-04 are discovered under cellular components (Fig. 6D).

3.1 Molecular Docking Analysis

The 3D structure of Calebin-A (SDF format) obtained from PubChem (CID: 637429) is indicated in Fig. (7). The specification of the 3D structure of TP53, TNF, STAT3, HSP90AA1, and PTGS2 achieved from the PDB database is reported in Table 3.

3.2 Pharmacokinetics and Physicochemical Properties of Calebin-A

The physicochemical and pharmacokinetics properties of the Calebin-A were predicted using SwissADME, and the achieved outcomes are exhibited in Fig. (8). Calebin-A prediction was observed to confirm Lipinski’s rule of five, Ghose, Veber, and Egan. The bioavailability score was 55%, and had good gastrointestinal (GI) absorption. Calebin-A showed non-inhibitory for several cytochrome P450 isoenzymes like CYP1A2, CYP2D6, and CYP2C19. Calebin-A, as reported by the SwissADME website, displayed good drug-likeness properties (Fig. 9).

The docking result of Calebin-A with TNF, STAT3, TP53, PTGS2, and HSP90AA1 was reported in Table 4, and their interactions were illustrated in Fig. (8). The results indicate that Calebin-A interacts with five essential hub proteins based on Binding Energy and H-bond observed. Calebin-A has a great binding with PTGS2 through five H-bonds and a binding affinity equal to -9.3 kcal/mol. It also indicated suitable interaction with STAT3 three H-bonds and -7.1 kcal/mol Binding Energy.

4 DISCUSSION

With the rising incidence of diabetes and obesity globally, the adverse effects of NAFLD are becoming a serious public health concern. NAFLD is one of the most common chronic liver diseases that can rapidly progress to other disorders, such as hepatocellular cancer. Calebin-A is a newly identified natural product that has structural similarity to curcumin, the bioactive pigment of turmeric [43-52]. Here, by using in silico tools, we showed the possible effect of Calebin-A on several critical genes involved in NAFLD. We demonstrated that Calebin-A could potentially target TP53, TNF, STAT3, HSP90AA1, PTGS2, HDAC6, ABCB1, CCT2, NR1I2, and GUSB, which are overexpressed in patients with NAFLD. We also showed that Calebin-A could impact several lipids metabolisms- and inflammation-related pathways and biological processes that participate in the progression of NAFLD. However, the most influenced pathway was the sphingolipid signaling pathway with SPHK2, SPHK1, PIK3R1, S1PR2, RAF1, TNF, CTSD, TP53, S1PR4, RELA, and NFKB1, VEGF signaling pathway with CASP9, SPHK2, SPHK1, MAPKAPK2, PIK3R1, RAF1, and PTGS2, C-type lectin receptor signaling pathway STAT1, MAPKAPK2, PIK3R1, RAF1, PTGS2, TNF, RELA, and NFKB1, and MAPK signaling pathway with DUSP3, MAPKAPK2, MKNK2, MAPT, CACNA1C, RAF1, TNF, TP53, RELA, and NFKB1. According to previous studies, these pathways were suggested to be involved in NAFLD.

Sphingolipids are linked to the development of hepatic insulin resistance [53, 54]. It has been shown that sphingosine-1-phosphate/ ceramide balance controls cell biology linked to hepatic damage stimulated by HFD [55].

An in-vitro study indicated that VEGFA could trigger human hepatic stellate cell (HSC) LX2 to take on a fibrogenic phenotype through VEGF-VEGFR signaling in a fatty acid media. Moreover, in the NAFLD-HCC group, a positive link between hepatic fibrosis and VEGFA was observed [56].

MAPK signaling pathway controls the nuclear factor E2-related factor 2 (Nrf2) and nuclear factor kappa B (NF-κB), which are implicated in liver and metabolic illnesses [57, 58]. In a mice model of diet-induced obesity, activation of MAPK signaling led to fat accumulation, inflammation, and the generation of reactive oxygen species (ROS) [59]. The advancement of NAFLD is accelerated by MAPK signaling, which also causes lipid buildup and inflammatory reactions [60, 61]. A promising approach for treating NAFLD/NASH is inhibiting the NF-B and MAPK cascades, reversing hepatic steatosis, inflammation, and aberrant lipid metabolism [62].

Calebin-A could potentially target TP53, TNF, STAT3, HSP90AA1, and PTGS2, which are implicated in NAFLD. In the gene expression (logFC: 0.91, P-Value: 9.04E-03) and PPI network (highest betweenness score: 0.23, Degree: 37, and Closeness score: 0.60) results, TNF was discovered as an essential hub gene involved in NAFLD that could be affected by Calebin-A. Docking analysis also indicated that Calebin-A could bind to the TNF-α (-6.5 kcal/mol) with two H-bonds, possibly suppressing TNF-α expression. TNF-α affects several processes connected to the pathogenic mechanisms of several human illnesses, including cellular activation and proliferation, inflammation, immune response, and cell death [63]. Calebin-A is crucial in controlling inflammatory responses and is connected to the pathogenesis of various inflammatory and autoimmune diseases [64]. Previous studies have shown that TNF-α is necessary for initiating NAFLD and its development into NASH by upregulating key molecules involved in inflammatory cytokines, lipid metabolism, and liver fibrosis [65]. Due to its role as the primary regulator of inflammatory cytokines, TNF-α has recently become recognized as a therapeutic target for several illnesses, including NAFLD. The development of NAFLD has been associated with activating pro-inflammatory cytokines, including TNF, in hepatocytes and adipose tissue [66]. Liver fat accumulation causes activation signals similar to the NF-kB via the upstream activation of IKK. TNF-α and other significant pro-inflammatory mediators are produced as a result of this activation, which induces the activation of Kupffer cells [67, 68]. TNF-α was highly up-regulated in the hepatocytes generated from mice fed with HFD. Earlier research also suggested that a high-carbohydrate diet (NAFLD-model) enhanced the amount of TNF-α in mouse liver [69, 70]. According to a randomized clinical trial, TNF-α was also considerably overexpressed in NAFLD patients [71]. Patients with steatohepatitis had greater blood TNF-α levels than healthy individuals with simple steatosis [72-74]. Moreover, the fibrotic stages were linked to the elevation of TNF and TNF-receptor-1 expression in the liver of patients with steatohepatitis [75]. In a preclinical study, Tomita et al. also confirmed that TNFR-deficient or TNF-deficient animal models of genetic or diet-induced NAFLD had better insulin sensitivity and less pronounced steatosis and fibrosis in the liver [76]. Calebin-A has been evaluated for its anti-inflammatory activity in several studies. Calebin-A could prevent IκBα degradation, nuclear translocation of p65-NF-κB, and NF-κB binding to DNA, thus preventing TNF-α induced canonical NF-κB activation [77, 78]. Other studies have reported that Calebin-A could block TNF-β like TNF-α [79-81].

In the pathogenesis of liver illnesses, the signal transducer and activator of transcription-3 (STAT3) plays a crucial role [4]. STAT3 belongs to the Janus kinase (JAK)/STAT pathway and is crucial in causing liver injury [82]. Deficiencies in STAT3 DNA-binding were reported to be mediated by increasing the expression of Pias3 in liver fibrosis [83]. STAT3 proteins were detected in high concentrations in the nucleus of proliferating biliary epithelial cells and hepatocytes from the liver of patients with cirrhosis [84]. STX-0119, a STAT3 dimerization inhibitor, was suggested to slow the progression of liver fibrosis by preventing the activation of hepatic stellate cells [85].

According to numerous investigations, STAT3 activity is also a survival signal that guards against lipotoxicity, whereas blocking hepatic STAT3 activation with other drugs reduces NAFLD-induced liver fibrosis [82]. In the NAFLD population, progressive fibrosis was linked to phosphorylation of STAT3, which is associated with an elevated risk for hepatocellular carcinoma (HCC) [86]. Recent research has shown that PNPLA3-mediated susceptibility to NAFLD was reduced by decreasing IL-6/STAT3 activity but increasing it in wild-type liver cells, promoting NAFLD onset. It was concluded that this function is due to bearing the rs738409 SNP that led to enhancing NF-κB activity, which is the cause of the heightened IL-6/STAT3 [87]. Calebin-A might regulate inflammatory pathways such as JAK/STAT3. The Janus kinases (JAKs), non-receptor cytoplasmic tyrosine kinases, are the primary promoters of STAT activation [17]. Several studies have suggested that curcumin may control the STAT3 signaling pathway. Most of these studies focus on STAT3's function in malignancies and the role of curcumin in suppressing them. Curcumin was shown to reduce STAT3 phosphorylation and block STAT3-mediated signaling [88]. In a previous study using an animal model of colitis, it was discovered that curcumin treatment drastically reduced STAT3 dimer DNA-binding activity and phospho-STAT3 activity [89]. A recent study found that STAT3 expression levels decreased in MDA-MB-231 cells following curcumin treatment [90]. By directly interfering with STAT3-mediated carcinogenesis, curcumin can abort atypical STAT3 activity [91]. However, no study has investigated the effect of Calebin-A on STAT3. In our PPI network analysis, we discovered STAT3 as a key protein interaction with a degree score of 31, a betweenness score of 0.58, and a closeness of 0.53, suggesting its importance in NAFLD. Calebin-A could modulate STAT3 through three H-bonds with a binding affinity energy of -7.1 kcal/mol.

TP53 is the genome's security factor, primarily as a tumor suppressor. It modulates a broad range of signaling pathways that inhibit oncogenic transformation [92]. p53 is thought to be a key player in the pathophysiology of NAFLD [93-98]. TP53 was discovered to be overexpressed in the livers of many NAFLD-plagued mouse models [98]. In normal sterol circumstances, TP53 directly and SREBP2 independently suppress the production of SQLE (squalene epoxidase), the first oxygenation enzyme and a rate-limiting step in cholesterol synthesis [99]. In mice given a HFD, TP53 activation was associated with hepatocyte apoptosis [96]. Moreover, in liver biopsy samples of human patients, there was a significant association between the degree of steatosis and p53 expression [97]. In a mouse model of NAFLD, the TP53 inhibitor pifithrin-p-nitro (PFT) caused attenuating steatosis, oxidative stress, and apoptosis [95]. According to these results, TP53 activation may be a widespread metabolic process that plays a significant role in the pathogenesis of fatty liver, regardless of the underlying cause, and that promotes apoptosis and oxidative stress and the development of harmful hepatic abnormalities like insulin resistance and steatosis. In one study, Calebin-A was shown to induce G2/M cycle arrest in human colon cancer cells by lowering the levels of the proteins cdc25A, cyclin A, cyclin B, and cdc2, and raising the levels of CDKIs like P21and TP53. Calebin-A also elevated levels of ROS, prompted a DNA damage response, and enhanced H2AX, chk2, and chk1 phosphorylation. Calebin-A administered intraperitoneally also dramatically reduced tumor diameter and volume [100]. Our obtained data displays that TP53 is one of the critical genes based on PPI network analysis (degree score: 40, betweenness score: 0.20, and closeness score: 0.63), which could be a possible target for NALFD. Calebin-A could strongly interact with TP53 by 6 H-bonds (-6.2 kcal/mol).

The HSP90AA1 is responsible for encoding heat shock protein 90α, which is triggered by stress and controls inflammation via several mechanisms. Previous research demonstrated that Hsp90α levels were higher in the serum of individuals with NAFLD, and there was a significant link between serum Hsp90 levels and steatohepatitis activity degree [101]. HSP90AA1 has been identified as one of the hub proteins in a PPI network analysis of GSE109836 [102]. In another in silico investigation of two datasets (GSE74656 and GSE62232), it was indicated that HSP90AA1 is a new pathogenic gene in the progression of NAFLD to HCC. The expression of HSP90AA1 was reported to be considerably decreased [103] in the liver of patients with alcoholic fatty liver disease (87). The level of HSP90AA1 could be repressed by curcumin administration [104]. However, there are no reports on the effect of Calebin-A on HSP90AA1. We observed HSP90AA1 as an effective hub gene in the PPI network, and the interaction with Calebin-A was through one H-bond (-6.9 kcal/mol).

The PTGS2 gene encodes an enzyme commonly known as cyclooxygenase two (COX-2) in the human body. The activation of PTSG2 has been linked to the etiology of several liver disorders, such as NAFLD, by enhancing hepatocyte lipid accumulation. Activation of PTSG2 after the establishment of type 2 diabetes and metabolic syndrome might have aggravating effects on the advancement of NASH [105]. PTGS2 is primarily associated with the role of gut flora in the onset and progression of NAFLD [106]. Calebin-A has been detected as a direct and non-selective inhibitor of PTSG1 and PTSG2 in several independent studies [10, 107]. As PTSG2 is one of the several NF-κB-dependent gene final products that play a significant role in many inflammatory processes, it is a main target for many traditional anti-inflammatory medicines [108]. PTGS2, discovered as an essential hub gene in DEGs and PPI network analyses, showed a strong interaction with Calebin-A (three H-bonds and a high affinity of -9.3 kcal/mol).

Throughout the early stages of drug discovery and development, computational prediction of bioavailability and drug-likeness qualities continues to be a crucial criterion in exploring drug candidates [43]. Physiologically based pharmacokinetic modeling software tools are being progressively used to forecast the pharmacokinetics and physicochemical properties of bioactive compounds or dosage forms [109]. Therefore, the physicochemical and pharmacokinetic properties of the Calebin-A were predicted using SwissADME, and the results are exhibited in Fig. (9). Calebin-A prediction was observed to conform to Lipinski’s rule of five, which showed a total polar surface area (TPSA) equal 102.29 Å2 (Fig. 9). The bioavailability score was in the range of 55%, suggesting a non-P-glycoprotein (P-gp) substrate and a suitable absorption in the gastrointestinal (GI) tract (Fig. 9). Calebin-A was reported as a non-inhibitor of cytochrome P450 isoenzyme (CYP1A2, CYP2D6, and CYP2C19) probes.

The conventional way for calculating lipophilicity is the octanol-water partition ratio. Different methods were designed to estimate this point's octanol-water partition ratio (logP). Lipinski's rule applied the Moriguchi-based algorithm to compute logP (MLOGP). The benefits of the Moriguchi technique are the simplicity of programming in all languages without needing a large database of parameter values [110].

According to the calculated ADME parameters, Calebin-A, which is an active compound against NAFLD, could be an oral drug since its MLOGP is equal to 1.49 (Recommended Range:- 2.0 to 6.5) and the log S (Recommended Range: -6.5 to 0.5) is equal to -4.01. Additionally, according to the rule of five, LogP value <5 (ideally 1.35-1.8) is suitable for oral and intestinal absorption, and Calebin-A (Consensus Log Po/w: 2.88) is considered moderately soluble in water [111]. Moreover, the ratio of carbons in the sp3 hybridization is 0.14 for saturation. Although the suitable range of Csp3 hybridization was not less than 0.25 [112], due to other ADME properties, Calebin-A could be considered to have sufficient oral bioavailability. Based on ADME findings, Calebin-A indicated good drug-likeness properties without any violations, and synthetic accessibility was equal to 3.24.

CONCLUSION

Based on computational analysis, our study demonstrated that Calebin-A has 87 common targets with NAFLD. Using PPI network analysis, we represented essential hub genes, including TP53, TNF, STAT3, HSP90AA1, and PTGS2, that are critical in NAFLD and might be influenced by Calebin-A. Here, we reported several pathways, such as those of sphingolipids, VEGFA, C-type lectin receptor, and MAPK, that are important in the progression of NAFLD and could be modulated by Calebin-A. By analyzing Calebin-A interaction with hub proteins, we displayed that Calebin-A could strongly bind to those overexpressed in NAFLD. Consequently, we assumed that Calebin-A might be a promising therapeutic candidate for NAFLD. Further experimental validation, such as in vitro and in vivo assays, are warranted to confirm the predicted interactions and elucidate the precise mechanisms Calebin-A exerts its anti-steatotic effects. Clinical trials can also be undertaken to evaluate the therapeutic efficacy and safety profile of Calebin-A for potential use in patients with NAFLD.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

ABCB1 ATP-binding Cassette Subfamily B Member 1

ADME Absorption, Distribution, Metabolism, and Excretion

AMPK AMP-activated Protein Kinase

CCT2 Chaperonin Containing TCP1 Subunit 2

COX-2 Cyclooxygenase Two

DEGs Differentially Expressed Genes

FAS Fatty Acid Synthase

GI Gastrointestinal

GUSB Glucuronidase Beta

HCC Hepatocellular Carcinoma

HDAC6 Histone Deacetylase 6

HFD High-fat Diet

HSC Hepatic Stellate Cell

HSP90AA1 Heat Shock Protein 90 Alpha Family Class A Member 1

JAKs Janus Kinases

MAPK Mitogen-activated Protein Kinase

MCODE Molecular Complex Detection

NAFLD Non-alcoholic Fatty Liver Disease

NASH Non-alcoholic Steatohepatitis

NF-κB Nuclear Factor Kappa B

NMR Nuclear Magnetic Resonance

NR1I2 Nuclear Receptor Subfamily 1

Nrf2 Nuclear Factor E2-related Factor 2

P-gp P-glycoprotein

PPARγ Peroxisome Proliferator-activated Receptor γ

PPI Protein-protein Interaction

PTGS2 Prostaglandin-endoperoxide Synthase 2

ROS Reactive Oxygen Species

SQLE Squalene Epoxidase

STAT3 Signal Transducer and Activator of Transcription 3

TNF Tumor Necrosis Factor

TP53 Tumor Protein p53

TPSA Total Polar Surface Area

VEGFA Vascular Endothelial Growth Factor A

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author at a reasonable request.

FUNDING

None.

CONFLICT OF INTEREST

Muhammed Majeed is the Founder and Chairman of Sabinsa Corporation and Sami- Sabinsa Group Limited.

Fig. (1) The flow chart of our study.

Fig. (2) Heatmap (A) and volcano map (B) of the DEGs in GSE135251.

Fig. (3) Intersection analysis of calebin-A-related targets and NAFLD-related genes using venn diagram.

Fig. (4) Illustration of the PPI network with 83 nodes and 315 edges and principal centralities identified in our study. The size of nodes clarifies the degree, and the intensity of node color clarifies betweenness.

Fig. (5) The three clusters were derived from MCODE analysis and were illustrated with different colors. The seed of each cluster is indicated with a V shape.

Fig. (6) Enrichment analysis for signaling pathways and gene ontology of 87 intersection protein/ genes using ClueGO. (A) Fifteen highest adjusted p-value and signaling pathway (KEGG) (B) Biological process (C) Molecular function (D) Cellular component.

Fig. (7) The 3D structure of calebin-A.

Fig. (8) Calebin-A binding site atoms interact with TNF, HSP90AA1, PTGS2, STAT3, and TP53.

Fig. (9) ADME properties of calebin-A by SwissADME.

Table 1 Protein targets of Calebin-A based on several prediction databases.

Prediction Databases	Calebin-A Targets	
swisstargetprediction	100	
prediction.charite.de	74	
Gdbtools	77	
Target net	136	
Sum of ALL	317	

Table 2 The scores of important centralities, fold-change, and FDR (In GSE135251) were reported.

Gene Symbol	Full Name	Degree	Betweenness	Closeness	logFC	Adjusted-P-value (FDR)	
TP53	Tumor protein p53	40	0.20	0.63	0.28	4.76E-02	
TNF	Tumor necrosis factor	37	0.23	0.60	0.91	9.04E-03	
STAT3	Signal transducer and activator of transcription 3	31	0.11	0.58	0.53	1.93E-03	
HSP90AA1	Heat shock protein 90 alpha family class A member 1	29	0.11	0.57	0.44	2.37E-02	
PTGS2	Prostaglandin-endoperoxide synthase 2	23	0.15	0.54	0.58	4.55E-02	
HDAC6	Histone deacetylase 6	16	0.07	0.48	0.73	3.68E-07	
ABCB1	ATP-binding cassette subfamily B member 1	14	0.05	0.49	1.54	1.58E-04	
CCT2	Chaperonin containing TCP1 subunit 2	12	0.06	0.46	0.63	2.54E-02	
NR1I2	Nuclear receptor subfamily 1 group I member 2	11	0.04	0.47	0.51	1.74E-02	
GUSB	Glucuronidase beta	7	0.44	0.29	0.24	2.45E-02	

Table 3 Specifications of the 3D structure proteins selected from the www.rcsb.org database.

Protein Target	PDB ID	Method	Resolution	Positions	
TNF	5UUI	X-ray diffraction	1.40 Å	77-233	
STAT3	6NJS	X-ray diffraction	2.70 Å	127-688	
TP53	6SL6	X-ray diffraction	1.67 Å	89-311	
PTGS2	5F19	X-ray diffraction	2.04 Å	2-552	
HSP90AA1	2YI7	X-ray diffraction	1.40 Å	1-229	

Table 4 The details of the interaction between calebin-A and five critical hub proteins.

Calenin-A-protein Interaction	Binding Energy (∆G) kcal/mol	H-bond	Donor Atom	Acceptor Atom	Distance	
Calebin A-TNF	-6.5	A:ARG32:HE - N:UNK1:O	HE	O	2.25859	
A:ALA33:HN - N:UNK1:O	HN	O	2.01347	
Calebin A-HSP90AA1	-6.9	A:ASN51:HD22 - N:UNK1:O	HD22	O	2.28889	
Calebin A-PTGS2	-9.3	B:HIS39:HD1 - N:UNK1:O	HD1	O	1.90427	
B:ARG44:HE - N:UNK1:O	HE	O	2.27225	
B:ARG44:HH11 - N:UNK1:O	HH11	O	2.41026	
B:CYS47:HN - N:UNK1:O	HN	O	2.47056	
B:CYS47:HN - N:UNK1:O	HN	O	2.40626	
Calebin A-STAT3	-7.1	A:GLN112:HE22-N:UNK1:O	HE22	O	2.32814	
A:SER358:HG - N:UNK1:O	HG	O	2.46437	
N:UNK1:H - A:GLU189:O	H	O	1.93606	
Calebin A-TP53	-6.2	A:ARG22:HE - N:UNK1:O	HE	O	2.06068	
A:ARG22:HH21 - N:UNK1:O	HH21	O	2.42515	
A:PHE25:HN - N:UNK1:O	HN	O	2.47878	
A:PHE25:HN - N:UNK1:O	HN	O	2.43234	
A:TYR38:HH - N:UNK1:O	HH	O	2.27153	
N:UNK1:H - A:ASN43:OD1	H	OD1	1.69958	
Abbreviations: UNK: Calebin-A, GLY: Glycine, VAL: Valine, LEU: Leucine, PHE: Phenylalanine, SER: Serine, ARG: Arginine, GLU: Glutamic acid, LYS: Lysine, CYS: Cysteine, ALA: Alanine, ASP: Aspartic acid, TYR: Tyrosine, ASN: Asparagine, THR: Threonine, GLN: Glutamine, HIS: Histidine, H: Hydrogen, O: Oxygen, N: Nitrogen, HD1: proton on the delta-Nitrogen of the Histidine.
==== Refs
REFERENCES

1 Li B Zhang C Zhan YT Nonalcoholic fatty liver disease cirrhosis: A review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol Jul 2; 2018 2784537 10.1155/2018/2784537 30065915
2 Machado M.V. Diehl A.M. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 2016 150 8 1769 1777 10.1053/j.gastro.2016.02.066 26928243
3 Mahmoudi A. Butler A.E. Jamialahmadi T. Sahebkar A. The role of exosomal miRNA in nonalcoholic fatty liver disease. J. Cell. Physiol 2022 237 4 2078 2094 10.1002/jcp.30699 35137416
4 Younossi Z. Anstee Q.M. Marietti M. Hardy T. Henry L. Eslam M. George J. Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018 15 1 11 20 10.1038/nrgastro.2017.109 28930295
5 Wree A Broderick L Canbay A Hoffman HM Feldstein AE Eslam M. George J. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013 Nov 10 11 627 36 Epub 2013 Aug 20. 10.1038/nrgastro.2013.149 23958599
6 Pouwels S. Sakran N. Graham Y. Leal A. Pintar T. Yang W. Kassir R. Singhal R. Mahawar K. Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 2022 22 1 63 10.1186/s12902-022-00980-1 35287643
7 Kim D.S.H.L. Kim J.Y. Total synthesis of calebin-A, preparation of its analogues, and their neuronal cell protectivity against β-amyloid insult. Bioorg. Med. Chem. Lett. 2001 11 18 2541 2543 10.1016/S0960-894X(01)00489-9 11549465
8 Majeed A. Majeed M. Thajuddin N. Arumugam S. Ali F. Beede K. Adams S.J. Gnanamani M. Bioconversion of curcumin into calebin-A by the endophytic fungus Ovatospora brasiliensis EPE-10 MTCC 25236 associated with Curcuma caesia. AMB Express 2019 9 1 79 10.1186/s13568-019-0802-9 31144200
9 Arafa H.M.M. Hemeida R.A. El-Bahrawy A.I.M. Hamada F.M.A. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem. Toxicol. 2009 47 6 1311 1317 10.1016/j.fct.2009.03.003 19285535
10 Oliveira A.L.D.P. Martinez S.E. Nagabushnam K. Majeed M. Alrushaid S. Sayre C.L. Davies N.M. Calebin A: Analytical development for pharmacokinetics study, elucidation of pharmacological activities and content analysis of natural health products. J. Pharm. Pharm. Sci. 2015 18 4 494 514 10.18433/J32310 26626247
11 Cheng A.L. Hsu C.H. Lin J.K. Hsu M.M. Ho Y.F. Shen T.S. Ko J.Y. Lin J.T. Lin B.R. Ming-Shiang W. Yu H.S. Jee S.H. Chen G.S. Chen T.M. Chen C.A. Lai M.K. Pu Y.S. Pan M.H. Wang Y.J. Tsai C.C. Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 21 4B 2895 2900 11712783
12 Nair A. Amalraj A. Jacob J. Kunnumakkara A.B. Gopi S. Non-curcuminoids from turmeric and their potential in cancer therapy and anticancer drug delivery formulations. Biomolecules 2019 9 1 13 10.3390/biom9010013 30609771
13 Mahmoudi A. Kesharwani P. Majeed M. Teng Y. Sahebkar A. Recent advances in nanogold as a promising nanocarrier for curcumin delivery. Colloids Surf. B Biointerfaces 2022 215 112481 10.1016/j.colsurfb.2022.112481 35453063
14 Majeed M. Nagabhushanam K. Natarajan S. Bani S. Pandey A. Karri S.K. Investigation of repeated dose (90 day) oral toxicity, reproductive/developmental toxicity and mutagenic potential of ‘Calebin A’. Toxicol. Rep. 2015 2 580 589 10.1016/j.toxrep.2015.03.009 28962393
15 Lai C.S. Liao S.N. Tsai M.L. Kalyanam N. Majeed M. Majeed A. Ho C.T. Pan M.H. Calebin-A inhibits adipogenesis and hepatic steatosis in high-fat diet-induced obesity via activation of AMPK signaling. Mol. Nutr. Food Res. 2015 59 10 1883 1895 10.1002/mnfr.201400809 26108684
16 Lee P.S. Lu Y.Y. Nagabhushanam K. Ho C.T. Mei H.C. Pan M.H. Calebin-A prevents HFD-induced obesity in mice by promoting thermogenesis and modulating gut microbiota. J. Tradit. Complement. Med. 2023 13 2 119 127 10.1016/j.jtcme.2022.01.001 36970457
17 Brockmueller A. Mueller A.L. Kunnumakkara A.B. Aggarwal B.B. Shakibaei M. Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. Front. Oncol. 2022 12 962066 10.3389/fonc.2022.962066 36185259
18 Oulas A. Minadakis G. Zachariou M. Sokratous K. Bourdakou M.M. Spyrou G.M. Systems Bioinformatics: Increasing precision of computational diagnostics and therapeutics through network-based approaches. Brief. Bioinform. 2019 20 3 806 824 10.1093/bib/bbx151 29186305
19 Mahmoudi A. Heydari S. Markina Y.V. Barreto G.E. Sahebkar A. Role of statins in regulating molecular pathways following traumatic brain injury: A system pharmacology study. Biomed. Pharmacother. 2022 153 113304 10.1016/j.biopha.2022.113304 35724514
20 Mahmoudi A. Atkin S.L. Nikiforov N.G. Sahebkar A. Therapeutic role of curcumin in diabetes: An analysis based on bioinformatic findings. Nutrients 2022 14 15 3244 10.3390/nu14153244 35956419
21 Mahmoudi A. Butler A.E. Majeed M. Banach M. Sahebkar A. Investigation of the effect of curcumin on protein targets in NAFLD using bioinformatic analysis. Nutrients 2022 14 7 1331 10.3390/nu14071331 35405942
22 Mao C. Howard T.D. Sullivan D. Fu Z. Yu G. Parker S.J. Will R. Vander Heide R.S. Wang Y. Hixson J. Van Eyk J. Herrington D.M. Bioinformatic analysis of coronary disease associated SNPs and genes to identify proteins potentially involved in the pathogenesis of atherosclerosis. J. Proteom. Genom. Res. 2017 2 1 1 12 10.14302/issn.2326-0793.jpgr-17-1447 29367937
23 Mahmoudi A. Butler A.E. Banach M. Jamialahmadi T. Sahebkar A. Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure. Curr. Probl. Cardiol. 2023 48 6 101660 10.1016/j.cpcardiol.2023.101660 36841313
24 Priscilla L. Viol Dhea K. Arif Nur Muhammad A. Muhammad Hermawan W. Rasyadan Taufiq P. Ahmad Affan Ali M. In Silico phytochemical compounds screening of allium sativum targeting the Mpro of SARS-CoV-2. Pharmacogn. J. 2022 14 3 604 609
25 Nur Sofiatul A. Viol Dhea K. Muhammad Hermawan W. Ahmad Affan Ali M. Rasyadan Taufiq P. Dora Dayu Rahma T. In silico screening of bioactive compounds from syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via tetra inhibitors. Pharmacogn. J. 2022 14 4
26 Melge A.R. Manzoor K. Nair S.V. Mohan C.G. In silico modeling of FDA-approved drugs for discovery of anti-cancer agents: A drug-repurposing approach. In silico drug design. Elsevier 2019 577 608
27 Mahmoudi A. Atkin S.L. Jamialahmadi T. Banach M. Sahebkar A. Effect of curcumin on attenuation of liver cirrhosis via genes/proteins and pathways: A system pharmacology study. Nutrients 2022 14 20 4344 10.3390/nu14204344 36297027
28 Daina A. Michielin O. Zoete V. Swiss target prediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019 47 W1 W357 W364 10.1093/nar/gkz382 31106366
29 Yao Z.J. Dong J. Che Y.J. Zhu M.F. Wen M. Wang N.N. Wang S. Lu A.P. Cao D.S. TargetNet: A web service for predicting potential drug–target interaction profiling via multi-target SAR models. J. Comput. Aided Mol. Des. 2016 30 5 413 424 10.1007/s10822-016-9915-2 27167132
30 Gallo K. Goede A. Preissner R. Gohlke B.O. SuperPred 3.0: Drug classification and target prediction—a machine learning approach. Nucleic Acids Res. 2022 50 W1 W726 W731 10.1093/nar/gkac297 35524552
31 Awale M. Reymond J.L. The polypharmacology browser: A web-based multi-fingerprint target prediction tool using ChEMBL bioactivity data. J. Cheminform. 2017 9 1 11 10.1186/s13321-017-0199-x 28270862
32 Clough E. Barrett T. The gene expression omnibus database. Methods Mol. Biol. 2016 1418 93 110 10.1007/978-1-4939-3578-9_5 27008011
33 Szklarczyk D. Gable A.L. Nastou K.C. Lyon D. Kirsch R. Pyysalo S. Doncheva N.T. Legeay M. Fang T. Bork P. Jensen L.J. von Mering C. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 49 D1 D605 D612 10.1093/nar/gkaa1074 33237311
34 Majeed A. Mukhtar S. Protein–protein interaction network exploration using cytoscape. Methods Mol. Biol. 2023 2690 419 427 10.1007/978-1-0716-3327-4_32 37450163
35 Bader G.D. Hogue C.W.V. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003 4 1 2 10.1186/1471-2105-4-2 12525261
36 Kim S. Chen J. Cheng T. Gindulyte A. He J. He S. Li Q. Shoemaker B.A. Thiessen P.A. Yu B. Zaslavsky L. Zhang J. Bolton E.E. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 2021 49 D1 D1388 D1395 10.1093/nar/gkaa971 33151290
37 Eberhardt J. Santos-Martins D. Tillack A.F. Forli S. AutoDock vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 2021 61 8 3891 3898 10.1021/acs.jcim.1c00203 34278794
38 Sharma P.K. Yadav I.S. Biological databases and their application. Bioinformatics. Elsevier 2022 17 31
39 Pettersen E.F. Goddard T.D. Huang C.C. Couch G.S. Greenblatt D.M. Meng E.C. Ferrin T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004 25 13 1605 1612 10.1002/jcc.20084 15264254
40 Dallakyan S. Olson A.J. Small-molecule library screening by docking with PyRx. Chemical biology. Springer 2015 243 250
41 Bindea G. Mlecnik B. Hackl H. Charoentong P. Tosolini M. Kirilovsky A. Fridman W.H. Pagès F. Trajanoski Z. Galon J. ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009 25 8 1091 1093 10.1093/bioinformatics/btp101 19237447
42 Qiu Y-Q. KEGG pathway database. Encyclopedia of Systems Biology. Dubitzky W. Wolkenhauer O. Cho K-H. Yokota H. New York, NY Springer New York 2013 1068 1069 10.1007/978-1-4419-9863-7_472
43 Panahi Y Sahebkar A. Amiri M Davoudi SM Beiraghdar F Hoseininejad SL Kolivand M. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2012 Oct 108 7 1272 9 Epub 2011 Nov 18. 10.1017/S0007114511006544 22099425
44 Cicero A.F.G. Sahebkar A. Fogacci F. Bove M. Giovannini M. Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur. J. Nutr. 2020 59 2 477 483 10.1007/s00394-019-01916-7 30796508
45 Kahkhaie K.R. Mirhosseini A. Aliabadi A. Mohammadi A. Mousavi M.J. Haftcheshmeh S.M. Sathyapalan T. Sahebkar A. Curcumin: A modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology 2019 27 5 885 900 10.1007/s10787-019-00607-3 31140036
46 Keihanian F. Saeidinia A. Bagheri R.K. Johnston T.P. Sahebkar A. Curcumin, hemostasis, thrombosis, and coagulation. J. Cell. Physiol. 2018 233 6 4497 4511 10.1002/jcp.26249 29052850
47 Khayatan D. Razavi S.M. Arab Z.N. Niknejad A.H. Nouri K. Momtaz S. Gumpricht E. Jamialahmadi T. Abdolghaffari A.H. Barreto G.E. Sahebkar A. Protective effects of curcumin against traumatic brain injury. Biomed. Pharmacother. 2022 154 113621 10.1016/j.biopha.2022.113621 36055110
48 Marjaneh R.M. Rahmani F. Hassanian S.M. Rezaei N. Hashemzehi M. Bahrami A. Ariakia F. Fiuji H. Sahebkar A. Avan A. Khazaei M. Phytosomal curcumin inhibits tumor growth in colitis‐associated colorectal cancer. J. Cell. Physiol. 2018 233 10 6785 6798 10.1002/jcp.26538 29737515
49 Mohajeri M. Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Crit. Rev. Oncol. Hematol. 2018 122 30 51 10.1016/j.critrevonc.2017.12.005 29458788
50 Mohammadi A. Blesso C.N. Barreto G.E. Banach M. Majeed M. Sahebkar A. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent. J. Nutr. Biochem. 2019 66 1 16 10.1016/j.jnutbio.2018.12.005 30660832
51 Mokhtari-Zaer A. Marefati N. Atkin S.L. Butler A.E. Sahebkar A. The protective role of curcumin in myocardial ischemia–reperfusion injury. J. Cell. Physiol. 2019 234 1 214 222 10.1002/jcp.26848 29968913
52 Panahi Y. Fazlolahzadeh O. Atkin S.L. Majeed M. Butler A.E. Johnston T.P. Sahebkar A. Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review. J. Cell. Physiol. 2019 234 2 1165 1178 10.1002/jcp.27096 30073647
53 Rodriguez-Cuenca S. Pellegrinelli V. Campbell M. Oresic M. Vidal-Puig A. Sphingolipids and glycerophospholipids: The “ying and yang” of lipotoxicity in metabolic diseases. Prog. Lipid Res. 2017 66 14 29 10.1016/j.plipres.2017.01.002 28104532
54 Musso G. Cassader M. Paschetta E. Gambino R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 2018 155 2 282 302.e8 10.1053/j.gastro.2018.06.031 29906416
55 Sztolsztener K. Konstantynowicz-Nowicka K. Harasim-Symbor E. Chabowski A. Time-dependent changes in hepatic sphingolipid accumulation and PI3K/Akt/mTOR signaling pathway in a rat model of NAFLD. Int. J. Mol. Sci. 2021 22 22 12478 10.3390/ijms222212478 34830360
56 Shen H. Yu H. Li Q. Wei Y. Fu J. Dong H. Cao D. Guo L. Chen L. Yang Y. Xu Y. Wu M. Wang H. Chen Y. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol. Sin. 2022 43 11 2917 2928 10.1038/s41401-022-00907-5 35508720
57 Peluso I. Yarla N.S. Ambra R. Pastore G. Perry G. MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Semin. Cancer Biol. 2019 56 185 195 10.1016/j.semcancer.2017.09.002 28912082
58 Lawan A. Bennett A.M. Mitogen-activated protein kinase regulation in hepatic metabolism. Trends Endocrinol. Metab. 2017 28 12 868 878 10.1016/j.tem.2017.10.007 29128158
59 Wu L. Liu Y. Zhao Y. Li M. Guo L. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Free Radic. Biol. Med. 2020 153 140 158 10.1016/j.freeradbiomed.2020.04.009 32311490
60 Zai W. Chen W. Wu Z. Jin X. Fan J. Zhang X. Luan J. Tang S. Mei X. Hao Q. Liu H. Ju D. Targeted interleukin-22 gene delivery in the liver by polymetformin and penetratin-based hybrid nanoparticles to treat nonalcoholic fatty liver disease. ACS Appl. Mater. Interfaces 2019 11 5 4842 4857 10.1021/acsami.8b19717 30628769
61 Zhang L. Tian R. Yao X. Zhang X.J. Zhang P. Huang Y. She Z.G. Li H. Ji Y.X. Cai J. Milk fat globule–epidermal growth factor–factor 8 improves hepatic steatosis and inflammation. Hepatology 2021 73 2 586 605 10.1002/hep.31277 32297339
62 Lu Y. Jiang Z. Dai H. Miao R. Shu J. Gu H. Liu X. Huang Z. Yang G. Chen A.F. Yuan H. Li Y. Cai J. Hepatic leukocyte immunoglobulin‐like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1‐TRAF6 pathway. Hepatology 2018 67 4 1303 1319 10.1002/hep.29633 29091299
63 Holbrook J. Lara-Reyna S. Jarosz-Griffiths H. McDermott M.F. Tumour necrosis factor signalling in health and disease. F1000 Res. 2019 8 111 111 10.12688/f1000research.17023.1 30755793
64 Jang D. Lee A.H. Shin H.Y. Song H.R. Park J.H. Kang T.B. Lee S.R. Yang S.H. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int. J. Mol. Sci. 2021 22 5 2719 10.3390/ijms22052719 33800290
65 Lu S. Wang Y. Liu J. Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies. J. Genet. Genomics 2022 49 4 269 278 10.1016/j.jgg.2021.09.009 34757037
66 Wandrer F. Liebig S. Marhenke S. Vogel A. John K. Manns M.P. Teufel A. Itzel T. Longerich T. Maier O. Fischer R. Kontermann R.E. Pfizenmaier K. Schulze-Osthoff K. Bantel H. TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis. 2020 11 3 212 10.1038/s41419-020-2411-6 32235829
67 Anderson N. Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008 60 3 311 357 10.1124/pr.108.00001 18922966
68 Cobbina E. Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD): Pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab. Rev. 2017 49 2 197 211 10.1080/03602532.2017.1293683 28303724
69 Ferreira A.V.M. Mario É.G. Porto L.C.J. Andrade S.P. Botion L.M. High-carbohydrate diet selectively induces tumor necrosis factor-α production in mice liver. Inflammation 2011 34 2 139 145 10.1007/s10753-010-9217-0 20446026
70 Oliveira M.C. Menezes-Garcia Z. Arifa R.D.N. Paula T.P. Andrade J.M.O. Santos S.H.S. Menezes G.B. Souza D.G. Teixeira M.M. Ferreira A.V.M. Platelet-activating factor modulates fat storage in the liver induced by a high-refined carbohydrate-containing diet. J. Nutr. Biochem. 2015 26 9 978 985 10.1016/j.jnutbio.2015.04.004 26013469
71 Saadati S. Sadeghi A. Mansour A. Yari Z. Poustchi H. Hedayati M. Hatami B. Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019 19 1 133 10.1186/s12876-019-1055-4 31345163
72 Hui J.M. Hodge A. Farrell G.C. Kench J.G. Kriketos A. George J. Beyond insulin resistance in NASH: TNF-? or adiponectin? Hepatology 2004 40 1 46 54 10.1002/hep.20280 15239085
73 Wellen K.E. Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005 115 5 1111 1119 10.1172/JCI25102 15864338
74 Uysal K.T. Wiesbrock S.M. Marino M.W. Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997 389 6651 610 614 10.1038/39335 9335502
75 Crespo J. Cayón A. Fernández-Gil P. Hernández-Guerra M. Mayorga M. Domínguez-Díez A. Fernández-Escalante J.C. Pons-Romero F. Gene expression of tumor necrosis factor [alpha ] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 6 1158 1163 10.1053/jhep.2001.29628 11732005
76 Tomita K. Tamiya G. Ando S. Ohsumi K. Chiyo T. Mizutani A. Kitamura N. Toda K. Kaneko T. Horie Y. Han J.Y. Kato S. Shimoda M. Oike Y. Tomizawa M. Makino S. Ohkura T. Saito H. Kumagai N. Nagata H. Ishii H. Hibi T. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006 55 3 415 424 10.1136/gut.2005.071118 16174657
77 Tyagi A.K. Prasad S. Majeed M. Aggarwal B.B. Calebin A, a novel component of turmeric, suppresses NF-κB regulated cell survival and inflammatory gene products leading to inhibition of cell growth and chemosensitization. Phytomedicine 2017 34 171 181 10.1016/j.phymed.2017.08.021 28899500
78 Buhrmann C Kunnumakkara AB Popper B Majeed M Aggarwal BB Shakibaei M Calebin a potentiates the effect of 5-FU and TNF-beta (Lymphotoxin alpha) against human colorectal cancer cells: Potential role of NF-kappa B. Inter. J. Mole. Sci. 2020 7 2393 10.3390/ijms21072393 32244288
79 Buhrmann C. Popper B. Kunnumakkara A.B. Aggarwal B.B. Shakibaei M. Evidence that calebin a, a component of curcuma longa suppresses NF-κB mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-β (Lymphotoxin). Nutrients 2019 11 12 2904 10.3390/nu11122904 31805741
80 Buhrmann C. Kunnumakkara A.B. Kumar A. Samec M. Kubatka P. Aggarwal B.B. Shakibaei M. Multitargeting effects of calebin A on malignancy of CRC cells in multicellular tumor microenvironment. Front. Oncol. 2021 11 650603 10.3389/fonc.2021.650603 34660256
81 Mueller A.L. Brockmueller A. Kunnumakkara A.B. Shakibaei M. Calebin A, a compound of turmeric, down-regulates inflammation in tenocytes by NF-κB/Scleraxis signaling. Int. J. Mol. Sci. 2022 23 3 1695 10.3390/ijms23031695 35163616
82 Zhao J. Qi Y.F. Yu Y.R. STAT3: A key regulator in liver fibrosis. Ann. Hepatol. 2021 21 100224 10.1016/j.aohep.2020.06.010 32702499
83 Stärkel P. De Saeger C. Leclercq I. Strain A. Horsmans Y. Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J. Hepatol. 2005 43 4 687 695 10.1016/j.jhep.2005.03.024 16098628
84 Stärkel P. Bishop K. Horsmans Y. Strain A.J. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans. Am. J. Pathol. 2003 162 2 587 596 10.1016/S0002-9440(10)63852-7 12547716
85 Choi S. Jung H.J. Kim M.W. Kang J.H. Shin D. Jang Y.S. Yoon Y.S. Oh S.H. A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice. Biochem. Biophys. Res. Commun. 2019 513 1 49 55 10.1016/j.bbrc.2019.03.156 30935693
86 Younes M. Zhang L. Fekry B. Eckel-Mahan K. Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD). Oncotarget 2022 13 1 1308 1313 10.18632/oncotarget.28324 36473131
87 Park J. Zhao Y. Zhang F. Zhang S. Kwong A.C. Zhang Y. Hoffmann H.H. Bushweller L. Wu X. Ashbrook A.W. Stefanovic B. Chen S. Branch A.D. Mason C.E. Jung J.U. Rice C.M. Wu X. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J. Hepatol. 2023 78 1 45 56 10.1016/j.jhep.2022.08.022 36049612
88 Liu Y. Wang X. Zeng S. Zhang X. Zhao J. Zhang X. The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma 06 biological sciences 0601 biochemistry and cell biology 11 medical and health sciences 1112 oncology and carcinogenesis. J. Exp. Clin. Cancer Res. 2018 37 1 303 10.1186/s13046-018-0959-0 30518397
89 Liu L. Liu Y.L. Liu G.X. Chen X. Yang K. Yang Y.X. Xie Q. Gan H.K. Huang X.L. Gan H.T. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int. Immunopharmacol. 2013 17 2 314 320 10.1016/j.intimp.2013.06.020 23856612
90 Mahata S. Behera S.K. Kumar S. Sahoo P.K. Sarkar S. Fazil M.H.U.T. Nasare V.D. In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics. Int. J. Biol. Macromol. 2022 208 356 366 10.1016/j.ijbiomac.2022.03.137 35346675
91 Hahn Y.I. Kim S.J. Choi B.Y. Cho K.C. Bandu R. Kim K.P. Kim D.H. Kim W. Park J.S. Han B.W. Lee J. Na H.K. Cha Y.N. Surh Y.J. Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells. Sci. Rep. 2018 8 1 6409 10.1038/s41598-018-23840-2 29686295
92 Chakraborty A. Uechi T. Kenmochi N. Guarding the ‘translation apparatus’: Defective ribosome biogenesis and the p53 signaling pathway. Wiley Interdiscip. Rev. RNA 2011 2 4 507 522 10.1002/wrna.73 21957040
93 Pani G. Fusco S. Colavitti R. Borrello S. Maggiano N. Cravero A.A.M. Farré S.M. Galeotti T. Koch O.R. Abrogation of hepatocyte apoptosis and early appearance of liver dysplasia in ethanol-fed p53-deficient mice. Biochem. Biophys. Res. Commun. 2004 325 1 97 100 10.1016/j.bbrc.2004.09.213 15522206
94 Derdak Z. Lang C.H. Villegas K.A. Tong M. Mark N.M. de la Monte S.M. Wands J.R. Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J. Hepatol. 2011 54 1 164 172 10.1016/j.jhep.2010.08.007 20961644
95 Derdak Z. Villegas K.A. Harb R. Wu A.M. Sousa A. Wands J.R. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol. 2013 58 4 785 791 10.1016/j.jhep.2012.11.042 23211317
96 Farrell G.C. Larter C.Z. Hou J.Y. Zhang R.H. Yeh M.M. Williams J. Dela Peňa A. Francisco R. Osvath S.R. Brooling J. Teoh N. Sedger L.M. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J. Gastroenterol. Hepatol. 2009 24 3 443 452 10.1111/j.1440-1746.2009.05785.x 19226377
97 Panasiuk A. Dzieciol J. Panasiuk B. Prokopowicz D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J. Gastroenterol. 2006 12 38 6198 6202 10.3748/wjg.v12.i38.6198 17036395
98 Yahagi N. Shimano H. Matsuzaka T. Sekiya M. Najima Y. Okazaki S. Okazaki H. Tamura Y. Iizuka Y. Inoue N. Nakagawa Y. Takeuchi Y. Ohashi K. Harada K. Gotoda T. Nagai R. Kadowaki T. Ishibashi S. Osuga J. Yamada N. p53 involvement in the pathogenesis of fatty liver disease. J. Biol. Chem. 2004 279 20 20571 20575 10.1074/jbc.M400884200 14985341
99 Sun H. Li L. Li W. Yang F. Zhang Z. Liu Z. Du W. p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. EMBO Rep. 2021 22 10 e52537 10.15252/embr.202152537 34459531
100 Liou W.S. Lin C. Lee P.S. Kalyanam N. Ho C.T. Pan M.H. Calebin-A induces cell cycle arrest in human colon cancer cells and xenografts in nude mice. J. Funct. Foods 2016 26 781 791 10.1016/j.jff.2016.08.047
101 Xie Y. Chen L. Xu Z. Li C. Ni Y. Hou M. Chen L. Chang H. Yang Y. Wang H. He R. Chen R. Qian L. Luo Y. Zhang Y. Li N. Zhu Y. Ji M. Liu Y. Predictive modeling of MAFLD based on Hsp90α and the therapeutic application of teprenone in a diet-induced mouse model. Front. Endocrinol. 2021 12 743202 10.3389/fendo.2021.743202
102 Asadzadeh-Aghdaei H. Zadeh-Esmaeel M.M. Esmaeili S. Rezaei Tavirani M. Rezaei Tavirani S. Mansouri V. Montazer F. Effects of high fat medium conditions on cellular gene expression profile: A network analysis approach. Gastroenterol. Hepatol. Bed Bench 2019 12 S130 S135 32099613
103 Cai Y. Jogasuria A. Yin H. Xu M.J. Hu X. Wang J. Kim C. Wu J. Lee K. Gao B. You M. The detrimental role played by lipocalin-2 in alcoholic fatty liver in mice. Am. J. Pathol. 2016 186 9 2417 2428 10.1016/j.ajpath.2016.05.006 27427417
104 Lv Y. Gong L. Wang Z. Han F. Liu H. Lu X. Liu L. Curcumin inhibits human cytomegalovirus by downregulating heat shock protein 90. Mol. Med. Rep. 2015 12 3 4789 4793 10.3892/mmr.2015.3983 26100249
105 Chan P.C. Liao M.T. Hsieh P.S. The dualistic effect of COX-2-mediated signaling in obesity and insulin resistance. Int. J. Mol. Sci. 2019 20 13 3115 10.3390/ijms20133115 31247902
106 Liu Y. Liu X. Zhou W. Zhang J. Wu J. Guo S. Jia S. Wang H. Li J. Tan Y. Integrated bioinformatics analysis reveals potential mechanisms associated with intestinal flora intervention in nonalcoholic fatty liver disease. Medicine 2022 101 36 e30184 10.1097/MD.0000000000030184 36086766
107 Novaes J. Lillico R. Sayre C. Nagabushanam K. Majeed M. Chen Y. Ho E. Oliveira A. Martinez S. Alrushaid S. Davies N. Lakowski T. Disposition, metabolism and histone deacetylase and acetyltransferase inhibition activity of tetrahydrocurcumin and other curcuminoids. Pharmaceutics 2017 9 4 45 10.3390/pharmaceutics9040045 29023392
108 Seibert K. Masferrer J.L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994 4 1 17 23 8038702
109 Palanichamy C. Pavadai P. Panneerselvam T. Arunachalam S. Babkiewicz E. Ram Kumar Pandian S. Shanmugampillai Jeyarajaguru K. Nayak Ammunje D. Kannan S. Chandrasekaran J. Sundar K. Maszczyk P. Kunjiappan S. Aphrodisiac performance of bioactive compounds from mimosa pudica linn.: In silico molecular docking and dynamics simulation approach. Molecules 2022 27 12 3799 10.3390/molecules27123799 35744923
110 Krstulović L. Leventić M. Rastija V. Starčević K. Jirouš M. Janić I. Karnaš M. Lasić K. Bajić M. Glavaš-Obrovac L. Novel 7-chloro-4-aminoquinoline-benzimidazole hybrids as inhibitors of cancer cells growth: Synthesis, antiproliferative activity, in silico adme predictions, and docking. Molecules 2023 28 2 540 10.3390/molecules28020540 36677600
111 Bhal S.K. LogP—making sense of the value. Toronto, ON, Canada Advanced Chemistry Development 2007 1 4
112 Daina A. Michielin O. Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017 7 1 42717 10.1038/srep42717 28256516
